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The role of the liver in the migration 
of parasites of global significance
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Abstract 
Many parasites migrate through different tissues during their life-cycle, possibly with the aim to enhance their fitness. 
This is true for species of three parasite genera of global importance, Ascaris, Schistosoma and Plasmodium, which 
cause significant global morbidity and mortality. Interestingly, these parasites all incorporate the liver in their life-
cycle. The liver has a special immune status being able to preferentially induce tolerance over immunity. This function 
may be exploited by parasites to evade host immunity, with Plasmodium spp. in particular using this organ for its 
multiplication. However, hepatic larval attrition occurs in both ascariasis and schistosomiasis. A better understanding 
of the molecular mechanisms involved in hepatic infection could be useful in developing novel vaccines and thera-
pies for these parasites.
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Background
The life-cycle of many parasites in their final host often 
involves migration from one tissue to another. The rea-
sons for this are unclear; however, tissue migration has 
been linked to increased body size and maturation, which 
leads to improved parasite survival [1]. A recent study 
[2] suggested that tissue migration enables the parasite 
to avoid eliciting an immune response, which is often 
raised at mucosal surfaces. If evading the host’s immune 
response is in fact a key purposes of this migration, the 
potential role of the liver becomes clear. The liver is an 
immunotolerant organ and therefore an ideal place for 
parasites to hide from the immune system. We will use 
human parasites of three genera, Ascaris, Schistosoma 
and Plasmodium, to illustrate the essential role of the 
liver in the life-cycle of these parasites. We will demon-
strate that the liver is a crucial step in their life-cycle, a 
point at which infection appears to go unnoticed, but a 
potential bottleneck where vaccination/treatment could 
be most effective.
Immunotolerance in the liver
The special immune status of the liver was first identified 
in transplantation experiments in pigs, where allogeneic 
liver transplants were not rejected as was the case with 
other organs [3, 4]. In humans some tolerance is observed 
whereby transplanted livers recover spontaneously after a 
rejection reaction [4] and some liver allograft recipients 
can even be completely withdrawn from immunosup-
pression [5].
Hepatic immunotolerance occurs through a combina-
tion of unique anatomical and histological features of 
the liver. Most of the blood that enters the liver comes 
directly from the portal system, making it the first organ 
to be exposed to gut-derived molecules including harm-
less bacterial products and nutrients [6]. The smallest 
unit of the liver, the hexagonal lobule, consists of a small 
layer of hepatocytes around a central vein. The capillary 
bed of the liver, the sinusoids, does not form tight junc-
tions, instead it forms fenestrations that are known as 
sieve plates [3]. The perisinusoidal space, also called the 
space of Disse, replaces the basement membrane to sep-
arate the liver sinusoidal endothelial cells (LSECs) from 
the hepatocytes [3].
The liver sinusoids are home to multiple populations of 
resident immune cells. These include myeloid leukocytes 
and liver parenchymal cells that express receptors that 
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sense pathogens, and myeloid and lymphoid cells capable 
of phagocytosis and cytotoxicity [7]. Central to the toler-
ogenic nature of the liver, the sinusoids contain multiple 
populations of antigen-presenting cells (APC) which pre-
sent antigenic peptides bound to major histocompatibil-
ity complex (MHC) molecules to T lymphocytes of the 
adaptive immune system [7–9]. Hepatic APCs are capa-
ble of activating T cells in vitro, inducing cytotoxicity 
and inflammatory cytokine secretion [7]. However, in the 
environment of the liver, hepatic APCs are more likely to 
inactivate T cells or induce their maturation into regula-
tory T (Treg) cells that suppress immune responses [3].
Antigen presentation to T cells is typically mediated by 
dendritic cells (DC) [10]. DCs express pathogen recep-
tors that enable them to recognise components of micro-
organisms that are not found in mammalian systems. 
They also express costimulatory and/or coinhibitory 
receptors and release cytokines that determine the nature 
of T cell activation or T cell tolerance. Antigen presenta-
tion by hepatic DC generally results in T cell inactivation 
by anergy or exhaustion. These tolerogenic DC can also 
drive the differentiation of naïve T cells into Treg cells, 
which release immunosuppressive cytokines and sup-
press the activities of other immune cells in an antigen-
specific manner [11–13].
Macrophages, known as Kupffer cells, are also abun-
dant in the liver sinusoids. Similar to other macrophages, 
two subsets of Kupffer cells (KC), defined by their phago-
cytic and cytokine-producing properties, have been 
described [14]. ‘Inflammatory’ or M1 macrophages 
secrete high levels of the proinflammatory cytokine IL-12 
and low levels of the regulatory cytokine IL-10, whereas 
‘alternatively-activated’ or ‘repair’ M2 macrophages, 
produce high levels of IL-10, TGF-β and low levels of 
IL-12 [15]. Upon pathogen receptor ligation, KCs most 
frequently act as M2 macrophages [16] and antigen-
presentation by these cells is frequently associated with 
expression of inhibitory ligands and cytokines and the 
induction of Treg cells [17, 18].
LSECs also express MHC and costimulatory molecules 
and are capable of presenting antigen to  CD8+ T cells 
leading to tolerance [19–21] and to  CD4+ T cells lead-
ing to their differentiation into Treg cells [22]. Hepatic 
stellate cells (HSC), also called Ito cells, can also present 
antigen to T cells [23], but again, antigen presentation by 
this APC preferentially promotes T cell tolerance [24, 25]. 
HSC can also promote the differentiation of monocytes 
into myeloid-derived suppressor cells (MDSC), which 
have potent T cell inhibitory activities [26]. Hepatocytes 
also express pathogen receptors, MHC and costimulatory 
molecules, although it is not clear these cells can present 
antigens to T cells leading to their activation [27, 28].
Three parasite genera of global importance: 
Ascaris, Schistosoma and Plasmodium
Species of the three parasite genera discussed in the pre-
sent review all use different ways to enter their final hosts, 
oral ingestion of eggs (Ascaris spp. [29]), skin penetration 
by free-swimming cercariae (Schistosoma spp. [30]), and 
injection into the blood stream via mosquito bites (Plas-
modium spp. [31]) (see Fig. 1). Despite entering different 
tissues, the parasites migrate to the liver rather quickly.
After egg-hatching in the gut, Ascaris spp. larvae are 
transported to the liver via the portal vein. Subsequently 
the larvae migrate to the lungs, where they are coughed 
up and swallowed thereby re-entering the gut [32]. The 
complexity of this life-cycle, in addition to the fact that 
both the start and end organ of the life-cycle are one 
and the same, the gut, indicates the importance of tissue 
migration, potentially related to increased fitness of the 
parasite.
Schistosoma spp. are slightly different, as the parasites 
migrate to the a different organ, the lungs first, before 
entering the liver and ultimately reaching the mesen-
teric vessels [30]. This is therefore the opposite path that 
Ascaris spp. larvae take. Although Schistosoma spp. reach 
the lungs first and the liver second, we will show that the 
role of the liver in the migratory path is still very impor-
tant in the larval development. In particular, in non-
immune animals, the liver appears to play an important 
role in parasite attrition.
Plasmodium sporozoites are injected into the skin by an 
infected mosquito and migrate to the liver via the blood-
stream [33] where the parasites mature into merozoites 
and multiply. Subsequently the merozoites are released 
in great numbers into the bloodstream and infect eryth-
rocytes where they mature into trophozoites, schizonts 
which release merozoites during asexual multiplication 
[33]. Ultimately trophozoites will mature into male and 
female gametocytes that can be picked up by a mosquito 
Fig. 1 The migratory path of Ascaris, Plasmodium and Schistosoma. Ascaris eggs are ingested orally and after hatching, larvae penetrate the gut wall. 
The larvae subsequently move to the liver and the lungs from where they are coughed up and swallowed thereafter establishing as adult worms 
in the gut. Plasmodium sporozoites are injected into the skin; from there they migrate to the liver where they multiply into merozoites. Merozoites 
leave the liver and infect erythrocytes where they eventually mature into gametocytes to continue the life-cycle. Schistosome cercariae are released 
into water from infected snails. Cercariae penetrate the skin and then migrate to the lungs and then the liver. Ultimately, these parasites establish 
themselves as adult worms in the mesenteric veins
(See figure on next page.)
Page 3 of 11Deslyper et al. Parasites Vectors          (2019) 12:531 
Page 4 of 11Deslyper et al. Parasites Vectors          (2019) 12:531 
bite. The liver is therefore used by the parasite as a ‘safe 
haven’ for the parasites to evade the hosts’ immune sys-
tem. It is also the place where hypnozoites from P. vivax 
can remain unnoticed for years before restarting their 
life-cycle and causing malaria pathology.
Ascaris: self‑cure and differential burden
Ascaris lumbricoides is a soil-transmitted helminth which 
infects 800 million people worldwide [34]. The eggs have 
a thick shell, making them highly resilient to various 
environmental factors such as temperature and desic-
cation [35]. Infections usually peak in children between 
5–15  years-old, who can experience symptoms ranging 
from growth retardation to diminished cognitive devel-
opment [35, 36].
Most infected individuals carry light worm burdens but 
a relatively small proportion harbour heavy infections, a 
distribution described as aggregated [37]. Predisposition 
to infection has also been observed in ascariasis, a phe-
nomenon whereby individuals are prone to a particular 
intensity of infection and regain similar worm burdens 
after treatment [38]. Although the exact mechanism of 
predisposition is unknown, it has been found to involve 
various factors, such as host genetics and adaptive immu-
nity [39].
While the liver stage appears to be clinically silent, the 
presence of macroscopical white spots, areas of inflam-
mation formed around the larvae due to injury during 
migration, in the liver of both humans infected with A. 
lumbricoides [40] and pigs infected with the porcine 
ascarid A. suum [41] is a clear indication that an immune 
response is generated. When treating experimentally 
infected pigs with anthelmintics during the liver stage 
(day 2, 3 and 4 post-infection, p.i.) of A. suum infection, 
an increase of 22% in their feed conversion rates, was 
found when compared to treating the pigs at the lung 
stage of infection (day 6, 7 or 8 p.i. [42]). As for humans, 
a prospective study of 510 Indian patients with liver 
abscesses during a 10-year period identified A. lumbri-
coides as the causative agent in 14.5% of the cases [40]. 
Similarly, a study in South African children demonstrated 
that A. lumbricoides was the causative agent of liver 
abscesses in 2% of the cases [43].
Self‑cure in pigs
Self-cure is a phenomenon observed in some pigs, where 
pigs receiving an oral trickle infection with A. suum eggs 
do not develop intestinal worms. The potential role of 
the liver in this phenomenon has received considerable 
attention.
In order to assess the role of the liver, an experiment 
was performed which bypassed the liver by infecting pigs 
with L3 stage (the lung stage) larvae through intravenous 
injection [44]. At day 21 p.i., a time at which self-cure 
usually has occurred, pigs did not show the typically 
observed decreased larval burden. This led the authors 
to believe that the liver played a crucial role in self-cure. 
However, the lack of a control group of orally infected 
pigs makes it hard to confirm this hypothesis. Another 
study approached the question of the role of the liver in 
self-cure by orally infecting pigs with lung-stage larvae 
[45]. The authors found first that self-cure still occurred, 
and secondly, that it happened at the same rate as their 
controls, i.e. pigs orally infected with embryonated eggs. 
A weep and sweep response has been attributed to this 
observation, whereby increased mucus secretion and gut 
movement eliminates the larvae before they can pene-
trate the gut wall [46]. Additionally, intestinal eosinophils 
and T cells were found to potentially play an important 
role. The mechanisms behind self-cure appear to be 
diverse and are not yet fully understood.
A mouse model for hepatic resistance
In order to study the liver stage of ascariasis, an appropri-
ate animal model is necessary. Building on earlier work 
[47], a mouse model has been developed specifically 
to study the predisposition phenomenon by using two 
inbred mouse strains which mimic the extremes of pre-
disposition to light and heavy infection [36, 48, 49]. CBA/
Ca and C57BL/6J were found to have a substantial and 
consistent difference in lung larval burden, with the for-
mer as the relatively resistant strain and the latter as the 
relatively susceptible strain.
This mouse model was subsequently used to investi-
gate when, during migration, this difference in larval bur-
den occurs [50]. Mice of both strains were infected with 
the same number of A. suum eggs. At regular intervals 
from 6  hours p.i. until 8  days p.i., mice were sacrificed 
and their organs (gut, liver, lungs) removed. The larvae 
were retrieved from those organs, using the modified 
Baermann method. The larvae were subsequently enu-
merated and counted. This allowed for detailed track-
ing of larval migration throughout the various organs. 
Using this mouse model, similar larval burdens were 
found in the liver of both strains [50]; however, once the 
larvae reached the lungs a significant difference in lar-
val burden was observed, with the relatively resistant 
strain having a lower burden than the relatively suscep-
tible strain. Another study found similar results, with 
no difference in total larval burden in the liver between 
the two strains [49]. The first larvae appear in the liver 
at 6 hours p.i. with a peak appearing between days 3–6, 
at this stage the larval burden is similar in both strains 
[50]. The larvae subsequently migrate to the lungs, with 
the first larvae appearing as early as day 1 p.i.; however, 
the majority of the larvae arrive around day 6 p.i. At this 
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point it becomes clear that one strain is relatively suscep-
tible (C57BL/6J) and another relatively resistant (CBA/
Ca), as there is a statistically significant difference in lung 
larval burdens between the two strains. Interestingly, 
the authors pointed out that there is a steady increase 
in mean larval burden in the liver between days 2 and 5 
p.i., long after the larvae should have penetrated the gut 
wall and made their way to the liver. The authors specu-
lated that “larvae were arriving from other locations and 
perhaps had become temporarily lost or trapped in other 
host tissues”, indicating a strong instinct for the larvae to 
make their way to the liver and highlighting the impor-
tance of this organ during migration.
The question then remains, which organ contributes 
most to this difference in infection rate, is it the departing 
organ, the liver, or the organ where the larvae arrive, the 
lungs. In order to explore this question in more detail, 
an investigation of the presence of various leukocytes in 
the bronchoalveolar fluids (BAL) in both strains of mice, 
infected with A. suum [50]. This study showed that an 
increase in leukocytes occurred at days 8–9 p.i., so only 
after the difference in larval burden had already occurred. 
Additionally, it was found that the increase in leukocytes 
in BAL was higher in the susceptible strain than in the 
resistant strain, indicating that this increase did not con-
tribute to the difference in larval burden between the two 
mouse strains but reflected the observed larval burden. 
This was confirmed in the same study by examining the 
lung tissue, in which was observed a greater inflamma-
tory response in the susceptible strain. Taken together, 
these data indicate the importance of the liver stage and 
that it plays a key role in the difference in infection rate 
between these two mouse strains.
Shotgun mass spectrometry was used to explore the 
liver proteome in the above mentioned mouse model at 
day 4 p.i. [51]. We observed a difference in abundance of 
mitochondrial proteins involved in oxidative phospho-
rylation. The relatively resistant strain (CBA/Ca) had, 
both intrinsically and under infection, higher levels of 
this protein group than the relatively susceptible strain 
(C57BL/6J). This led us to believe that a potential intrin-
sic difference in reactive oxygen species (ROS) in the liver 
gives the relatively resistant strain an advantage in con-
tending with the parasite.
A subsequent study investigated the difference in liver 
proteome at day 7 p.i. This study confirmed the earlier 
findings of day 4 p.i., demonstrating that the relatively 
resistant strain had a higher abundance of proteins 
involved in oxidative phosphorylation. However, the later 
day experiment revealed an important difference in the 
immune response to A. suum in the liver, with the rela-
tively susceptible strain showing a higher abundance of 
proteins involved in complement inactivation compared 
to the relatively resistant strain which had a higher abun-
dance of proteins involved in complement activation 
[52]. These two studies demonstrate the importance of 
delineating host responses to helminth infection at differ-
ent time points post-infection.
During a reinfection experiment [53], BALB/c mice 
were infected with A. suum, the authors found no differ-
ence in the liver larval burden when comparing mice that 
were infected once or reinfected. However, a lower larval 
burden was observed in the lungs in the reinfected mice, 
and more importantly, lesions caused by hepatocyte 
necrosis and infiltration of eosinophils and neutrophils 
were more pronounced in the reinfected group. These 
results indicate that the observed, more pronounced 
hepatic immune response in the reinfected group results 
in a decrease in lung larval burden.
To conclude, the presence of white spots indicates the 
presence of a strong immunological response in the liver. 
The liver stage becomes particularly important when 
investigating predisposition in pigs, mice and humans. 
Novel therapies could therefore focus on the liver in 
order to stop larval migration in its tracks, prevent 
increased damage due to larval migration and ultimately 
inhibit the development of adult worms which have sig-
nificant impact on the nutritional and developmental sta-
tus of the host [51, 54].
The liver as a site for attrition in Schistosoma 
infection
Species of Schistosoma infect over 250 million people 
worldwide [30]. Reinfections are common in endemic 
regions, with children often having suffered their first 
infection by the age of two, followed by a steady increase 
in worm burden with every new infection [55]. After 
these early infections, the worm burden decreases with 
increased exposure to the parasite that is thought to 
increase immunity, combined with the death of older 
worms [30].
Schistosoma spp. interact with the liver during two dis-
tinct parts of their life-cycle. First, for all human Schis-
tosoma species, the immature worms pass through the 
liver’s vasculature after lung migration. Secondly, after 
the migratory path has been completed and the adult 
worms are located in the mesenteric vessels, some 
excreted eggs however do not end up in the faeces but 
instead travel to the liver via the hepatic vessel, this is 
true for all human Schistosoma species except S. hae-
matobium. Schistosoma haematobium is the only spe-
cies that does not cause liver pathology, as the adult 
worms are located in the venus plexus of the bladder 
[56]. In order to break down the eggs, granulomas are 
formed around them, causing hepatic fibrosis, which is 
the main source of mortality and morbidity in chronic 
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schistosomiasis [57]. Liver-associated disease in schisto-
somiasis is more common in S. japonicum and S. man-
soni infections [58]. The liver is also profoundly impacted 
due to the longevity of the adult worms with an average 
life span of 3–10 years [59]. In essence, the most damag-
ing symptoms associated with Schistosoma spp. infection, 
hepatic granuloma formation does not occur until after 
larval migration is completed and can be considered an 
unwanted side effect.
The liver as a site for maturation, pairing 
and sexual development
The liver stage is a crucial phase in the life-cycle of schis-
tosomes, it is here that they can increase their biomass 
and develop into mature life stages [60, 61]. These impor-
tant life-cycle changes do not occur at any other stage, in 
fact, schistosomulae of S. mansoni which were trapped in 
the pulmonary vasculature were not able to reach matu-
rity [60, 62]. Parasites that reached the liver, however, 
showed exponential growth, thus demonstrating that the 
liver’s vasculature alone can provide the parasites with an 
adequate environment to reach maturity. Additionally, it 
was found that culturing S. mansoni schistosomulae in 
the presence of human portal serum showed a significant 
increase in cell proliferation when compared to schis-
tosomula cultured in the presence of human peripheral 
serum [63, 64], again confirming that the liver vascula-
ture provides the optimal environment for these para-
sites. However, so far it is not clear which components 
contribute, or might be essential for these processes to 
occur.
Additionally, it is at the liver stage that male and female 
parasites pair, which allows the females to reach sexual 
maturity; females cannot reach sexual maturity with-
out the presence of males [65]. The paired schistosomes 
subsequently migrate against the blood flow to the mes-
enteric veins [66]. The fact that these parasites need to 
manoeuvre against the blood flow, a process that female 
parasites cannot do by themselves [66] highlights again 
the importance of the liver stage for this parasite.
Attrition: when, where and how?
The site of attrition has been a topic of contention for 
decades, it was studied intensively in the 1980s thanks 
to the development of the autoradiographic tracking [67] 
which greatly improved the sensitivity of these experi-
ments. Using this technique, it was found that between 
86% and 90% of the skin-penetrant cercariae in naïve 
mice (i.e. mice that received a single round of infection) 
had migrated to the lungs, indicating that the skin was 
not the site of attrition [68, 69]. Further investigation 
of the migration of S. mansoni, using autoradiographic 
tracking in C57BL/6 mice showed a peak in the lungs at 
day 8 and in the systemic organs at day 12 [70]. All this 
indicates attrition occurring between the pulmonary 
and hepatic life stages of the parasite [68]. This raises 
the question as to why these parasites move to the liver 
next - perhaps the liver is a safe haven - a place where the 
parasites are no longer under attack and can reach sexual 
maturity safely hidden from the immune system.
As for immunized animals, which were immunized 
through either gamma-irradiated cercariae or establish-
ing a chronic infection, the attrition is largely similar to 
that of naïve animals, except that everything appears to 
go more slowly, i.e. migration from the skin to the lungs 
takes longer and peak burden in the lungs was at a later 
time point. The big difference with naïve animals is the 
lower number of parasites reaching the systemic and 
splanchnic organs [70–73].
The location of attrition varies between Schistosoma 
species. For S. mansoni and S. haematobium attrition 
mainly occurs in the lungs [74, 75]. However, five times 
more S. mansoni larvae reached the liver than is the case 
for S. haematobium. This observed greater larval death in 
S. haematobium infection can be partially attributed to 
the fact that mice are non-permissive hosts for this para-
site [76]. Attrition in S. japonicum was found to occur in 
both the lungs and the liver [77].
Regardless of whether the lungs or the liver are the 
main site of larval removal, it is still crucial to investigate 
the role of the liver in the life-cycle, which could also be 
a potential target for vaccination. Early removal of the 
parasite, before it reaches sexual maturity and therefore 
egg-laying, would reduce granuloma formation.
Multiplication of Plasmodium in the liver
The protist parasites Plasmodium spp. are the causa-
tive agents of malaria in humans, resulting in an esti-
mated 429,000 deaths in 2015 [78]. There are five species 
that infect humans: P. falciparum, P. ovale, P. vivax, P. 
malariae and P. knowlesi. Of these, P. falciparum infec-
tion is the most common and pathogenic, causing 99% of 
malaria associated deaths [78].
Malaria-associated pathology is often divided into 
uncomplicated and severe P. falciparum malaria. Uncom-
plicated malaria results in general malaise [31]. Severe 
falciparum malaria is caused by P. falciparum sequester-
ing in the small and medium-sized blood vessels of dif-
ferent organs particularly the brain [31]. Pathology in 
humans is therefore mainly associated with the blood 
stages of the parasite and complications thereof such as 
cerebral malaria [31]. The lack of symptoms and the brief 
duration of the liver stage, make it a particularly difficult 
stage to study. However, a recent study using malaria-
naïve human volunteers who were infected with P. fal-
ciparum through infective bites observed an increase in 
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total leukocyte, lymphocyte and monocyte count during 
the liver stage followed by a decrease in the aforemen-
tioned counts when the blood stage is initiated [79].
The liver is the only organ necessary for Plasmodium 
spp. maturation. At this stage a low number of sporozo-
ites proliferate into a large numbers of merozoites, ready 
to invade erythrocytes and start the process of the well-
known cyclic fever bouts. Due to this bottleneck, the 
liver stage forms an ideal target for vaccination purposes. 
However, before a vaccine can be developed, an in-depth 
understanding of this stage is necessary. The National 
Institute of Allergy and Infectious Diseases recently 
identified ‘greater understanding of parasite liver-stage 
biology and development’ as a key challenge in malaria 
vaccine development [80].
The path to the liver
After being deposited in the skin from a mosquito bite, 
sporozoites migrate to the liver via the blood. To enter 
the liver, the sporozoites must cross the fenestrated 
endothelial layer; however, the fenestrations are too small 
for the sporozoites to pass through, thus passage must 
go through the sinusoidal cells [81]. Circumsporozoite 
protein (CSP) and thrombospondin-related anonymous 
protein (TRAP), expressed by sporozoites, binds human 
heparin sulphate proteoglycans (HSPGs), the signal for 
sporozoites to leave the blood stream [82, 83]. Whether 
the sporozoites invade the liver through KC invasion 
or not is still under debate, with some studies suggest-
ing a necessary step through KCs [84, 85], whereas oth-
ers indicating that hepatocytes can be invaded directly 
[86]. Some studies suggest that sporozoites need to travel 
through KCs, whereas others indicating that hepatocytes 
can be invaded directly. Sporozoites have been shown 
to directly infect hepatocytes in vitro and develop into 
merozoites; however, due to the cellular structure of the 
liver it has been suggested that in vivo the sporozoites 
must pass through KCs [84]. Frevert et al. [85] described 
the migration of the sporozoites with an abrupt speed 
change, at which point they glide along LSECs, followed 
by a long pause for the sporozoites to enter the KCs, 
which the authors attribute to formation of nonfusogenic 
vacuole formation and a relatively slow passage through 
the KCs. CSP from sporozoites has been shown to ele-
vate cAMP levels in KCs, thereby inhibiting the cells 
from producing a respiratory burst and thus protecting 
the sporozoites [87]. Additionally, sporozoite micro-
neme protein essential for cell traversal 2 (SPECT2) defi-
cient sporozoites were not able to infect the liver in vivo 
[88]. These data suggest the need of KCs in hepatocyte 
infection.
However, a recent study provided evidence for the 
alternate hypothesis [86]. The authors, building on earlier 
work [89], identified that 17% of sporozoite cell traversals 
exclusively involve endothelial cells [86]. They also identi-
fied that 15% of crossing events were independent of cell 
traversal and KCs, which could be the sporozoite moving 
between two endothelial cells or between an endothe-
lial cell and a KCs. Furthermore, the authors found that 
sporozoites KCs traversal is associated with cell death of 
those KCs.
Regardless of this, sporozoites will eventually migrate 
through several hepatocytes, for yet unknown reasons, 
using a transient vacuole to ensure passage [85]. Three 
theories exist as to why the Plasmodium parasites travel 
through several hepatocytes before forming the PV and 
ultimately differentiating into merozoites. The first the-
ory argues several rounds of migration through hepato-
cytes might be a protective mechanism by the parasite to 
ensure that formation of the PV and subsequent mero-
zoites formation only occurs in the liver and not in the 
other tissues (skin, etc.) [89]. A second theory builds on 
the observation that hepatocyte growth factor is released 
when the parasite migrates through hepatocytes this 
induces neighbouring hepatocytes to be more suscepti-
ble to infection [90]. Thirdly, it has been suggested that 
upon detection of high sulphated HSPGs, the sporozoites 
turn off their traversal machinery and activate the inva-
sion machinery; however, this has been shown to take 
between 30–60 min in Plasmodium yoelii, which would 
explain the invasion of multiple hepatocytes [91, 92]. 
When reaching their final hepatocyte, a parasitophorous 
vacuole (PV) is formed and the sporozoites can differen-
tiate into merozoites [85].
The merozoites will then need to pass the space of 
Disse, at which stage they are vulnerable to KC phagocy-
tosis [93]. To avoid this, the infected hepatocytes release 
merozoite-filled vesicles, which are derived from the 
plasma membrane of hepatocytes, into the liver sinusoids 
[93, 94]. The phosphatidylserine switch is prevented in 
these merozoites-filled vesicles so as not to alert the KC 
and other immune cells, granting an escape route for the 
parasite [93].
Hypnozoites
Hypnozoites have only been observed in P. vivax [95], 
although a handful of cases of relapsing P. ovale have 
been seen as well, but without confirmation of hypnozo-
ites [96]. This life stage arguably exploits the liver’s spe-
cial immune status to the fullest. By going into a dormant 
state in the liver, for weeks or months, these parasites can 
hibernate and resume infection [97]. No study so far have 
been able to identify the triggers for hypnozoites reacti-
vation, nor its specific relationship to the liver.
The importance of these hypnozoites, which can 
remain dormant for 6–9  months, cannot be overstated 
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if the ultimate goal is malaria elimination [98, 99]. Up to 
80% of all blood stage P. vivax infections are attributed 
to relapses; however, not all relapses can be attributed to 
hypnozoites and other mechanisms are thought to be at 
play [100–102]. Investigating these hypnozoites more in 
depth could give a better insight in to why Plasmodium 
spp. incorporate the liver in the life-cycle and how they 
exploit hepatic immune tolerance.
Hepatic immunity
Naturally acquired immunity is probably not achieved at 
the liver stage, rather it is more likely an antibody-medi-
ated response to the blood stage [33]. However, the liver 
stage offers a great opportunity to activate the immune 
system and eliminate the relatively few sporozoites before 
they multiply greatly in numbers and spread all over the 
body via the blood.
Innate recognition of Plasmodium RNA by melanoma 
differentiation-associated gene 5 protein (MDA5) and 
mitochondrial antiviral signalling (MAVS) pathway in 
infected hepatocytes induces activation of the transcrip-
tion factors interferon-regulatory factors-3 (Irf3) and 
IRF7 [103]. Additionally, a recent in vivo study showed 
that protection against clinical malaria in children is 
associated with C1q-fixing antibodies against CSP in P. 
falciparum sporozoites [104]. These antibodies inhibited 
hepatocyte cell traversal and ultimately induced sporozo-
ite death.
CD8+ T cells play an important role in immunity to 
malaria, with  CD8+ T-cell depleted mice being unable to 
develop immunity [105]. The efficacy of parasite inhibi-
tion is therefore dependent on the availability of effec-
tor  CD8+ T cells [106]. Some  CD8+ T cells get primed 
by dendritic cells in the skin draining lymph nodes before 
moving to the liver where they eliminate antigen present-
ing hepatocytes [107]. No evidence exists that hepato-
cytes can successfully present antigen and activate naive 
 CD8+ T cells, however, hepatocytes can present a CSP 
epitope of P. berghei to primed  CD8+ T cells [106].
To ensure full inhibition of blood stage malaria devel-
opment 100% immunity is required. To achieve this, the 
very low number of hepatocytes that are actually infected 
has to be fully eliminated in the relatively short hepatic 
period, meaning that there is a need for a very large 
threshold of memory T cells to ensure immunity after 
epitope-specific immunization [106].
In short, the immune response in the liver is not fully 
elucidated yet and knowledge appears to be lacking. Plas-
modium spp. likely exploit the immunotolerance of the 
liver to increase the relatively small number of sporo-
zoites to a much larger number of merozoites. The liver 
stage therefore forms an ideal target for vaccine develop-
ment. If successful, a vaccine would be able to stop the 
infection before any symptoms occur and would elimi-
nate the spread of malaria, thus also contributing to its 
elimination.
While the liver offers a immunotolerogenic environ-
ment for the maturation of species of Ascaris, Schisto-
soma and Plasmodium, it should be noted that the liver 
has many other attributes that make it an attractive resi-
dence for these parasites. The liver sinusoids comprise 
a network of capillaries containing nutrient-rich blood 
from the intestine. The low blood pressure in the sinuses 
may offer an environment that supports growth, matura-
tion and/or multiplication. Furthermore, the liver has a 
unique ability to regenerate and remodel itself, an attrib-
ute which could be exploited by the parasites to limit the 
deleterious effects of infection and inflammation and 
preserve their host tissue. The propensity of the liver to 
induce tolerance of foreign antigens, rather than immu-
nity, is another attribute that may attract parasites, as 
well as other microorganisms, to this organ.
Conclusions
Immunologically the liver is a special organ where 
immune activation is reduced. This forms the ideal envi-
ronment for species of Ascaris, Schistosoma and Plasmo-
dium to mature to their next life stages, and multiply as 
is the case for Plasmodium spp. only. When migrating 
to the liver, the parasites are able evade the immune sys-
tem. However, this does not always go according to plan. 
In the case of both Schistosoma spp. and Ascaris spp., 
the liver has been identified as a site of larval attrition. 
Understanding the molecular mechanisms behind this 
attrition could lead to the development of novel thera-
pies. As for Plasmodium spp., the liver is a true bottle-
neck. It is at this life stage that the parasites multiply 
rapidly, before being released in the blood and spreading 
all over the host. The liver stage is therefore the ideal vac-
cine/drug target, as the parasite is still in relatively low 
numbers and concentrated in one organ. In short, the 
liver stage is understudied and more research is neces-
sary to fully understand the molecular mechanisms and 
immune responses activated during parasitic invasion.
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